Rio Biopharmaceuticals is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $19.3B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Rio Biopharmaceuticals's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Ozempic | Novo Nordisk | Generic | 2032 | Settled, terms confidential | ≈$19.3B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Rio Biopharmaceuticals's share of it.